ArticleThe Pediatric infectious disease journal2011
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.
Article in The Pediatric infectious disease journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.Antimicrobial agents and chemotherapy · 2013Trial
- Characteristics of children with influenza admitted to a pediatric hospital in Greece during the 2022/2023 and 2023/2024 seasons.European journal of pediatrics · 2025Observational
- Approach to hematopoietic cell transplant candidates with respiratory viral detection.Frontiers in pediatrics · 2023Review
- Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 withEmerging microbes & infections · 2021Article
- Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.Viruses · 2021Review
- Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.Antiviral research · 2020Article
- Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.The Journal of antimicrobial chemotherapy · 2019Article
- Article
- Article
- Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.Antimicrobial agents and chemotherapy · 2018Article
- Genome-wide characterization of the seasonal H3N2 virus in Shanghai reveals natural temperature-sensitive strains conferred by the I668V mutation in the PA subunit.Emerging microbes & infections · 2018Article
- Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.Frontiers in microbiology · 2018Review
- A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.Antiviral research · 2017Article
- Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.Scientific reports · 2017Article
- Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Article
- Genetic and antigenic characterization of influenza A(H3N2) in Cameroon during the 2014-2016 influenza seasons.PloS one · 2017Article
- Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.Immunology and cell biology · 2016Article
- Reducing the impact of influenza-associated secondary pneumococcal infections.Immunology and cell biology · 2016Article
- Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Journal of virology · 2015Article
- Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.Influenza and other respiratory viruses · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundImmunocompromised patients are highly susceptible to influenza infection and can have prolonged viral shedding, which is a risk factor for the development of antiviral resistance.
methodsWe investigated the emergence of oseltamivir-resistant influenza variants in children and young adults with cancer during the 2002-2008 influenza seasons. The demographic and clinical features of influenza infections in 12 patients who had viral isolates obtained before and after oseltamivir therapy was initiated were studied. Antiviral susceptibilities were determined by the fluorescence-based neuraminidase (NA) enzyme inhibition assay and by sequencing genes encoding NA and matrix M2 proteins.
resultsThe mean age of patients was 10.5 (range, 1.1-23.0) years. Ten patients had hematologic malignancies, 4 were recipients of hematopoietic stem cell transplants, and all patients were receiving immunosuppressive therapy. Eleven patients had prolonged respiratory symptoms and 8 had prolonged viral shedding. Serial viral isolates were available for 8 of 12 patients. Oseltamivir-resistant influenza viruses were isolated from 4 children (3 influenza A [H3N2] and 1 influenza B virus): before the initiation of antiviral therapy in 2 patients and during therapy in the other 2 patients. Three resistant influenza A (H3N2) viruses shared a common E119V NA mutation. One patient was infected with oseltamivir-resistant influenza B virus (IC50, 731.86 ± 155.12 nM) that harbored a N294S NA mutation, the first report of this mutation in influenza B viruses.
conclusionsOseltamivir-resistant influenza viruses can exist before or rapidly emerge during antiviral therapy in immunocompromised individuals, and this has important implications for therapy and infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.